Staffan Strömberg

Staffan holds a PhD from KTH Royal Institute of Technology in Stockholm and has over 23 years of experience in the pharmaceutical industry. He is currently CEO of Infant Bacterial Therapeutics AB.

Besides his role as Head of Medical Devices at the Swedish Medical Products Agency, he has also been Vice President of Nicox France, and had management positions at AstraZeneca.

Staffan has particularly experience in the development of orphan drugs as he was Head of R&D of Swedish Orphan.